| Filed On | Filing |
|---|---|
| 03 Nov 2026 | SCHEDULE 13D/A |
| 27 Oct 2026 | 10-Q |
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, October 27, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026. |
| 18 Sep 2026 | EFFECT |
| 18 Sep 2026 | 424B5 |
| 11 Sep 2026 | SCHEDULE 13D/A |
| 11 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Nautilus Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: |
| 11 Sep 2026 | S-3 |
| 28 Aug 2026 | SCHEDULE 13D/A |
| 14 Aug 2026 | SCHEDULE 13D/A |
| 28 Jul 2026 | 10-Q |
| 28 Jul 2026 |
8-K: Results of Operations and Financial Condition
SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. |
| 30 Jun 2026 | SCHEDULE 13D/A |
| 22 Jun 2026 |
Form 4: Posard Matthew L., Director
Granted 45,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Nazem Farzad, Director
Granted 45,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Akinsanya Karen, Director
Granted 45,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: McIlwain Matthew S, Director
Granted 45,000 Stock Option (Right to Buy) |
| 22 Jun 2026 |
Form 4: Epperly Melissa B,, Director
Granted 45,000 Stock Option (Right to Buy) |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Nautilus Biotechnology, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 17, 2026 (the “Annual Meeting”). Of the 127,078,855 shares of the Company’s common stock outstanding as of the record date of April 20, 202... |
| 04 Jun 2026 | SCHEDULE 13D/A |
Loading...